Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangzhou, China

Survival: 18.1 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: China
City/State/Province: Guangzhou
Hospital: Guangdong Lung Cancer Institute, Guangdong General Hospital
Journal: Link
Date: 9/2012

This phase 3 study involved untreated advanced non-small cell lung cancer patients who were divided into two separate treatment groups. Of the total patient population, 78.5% were female and 82.5% were less than 65 years of age. There were 184 patients in group A and 188 in group B.

Patients in group A were treated with the biologic therapy agent gefitinib, which is an inhibitor of EGFR and interferes with cancer cell growth.

Patients in group B were treated with the chemotherapy agents carboplatin and paclitaxel.

The most severe toxicities in group A were of grade 4 and included grade 3-4 diarrhea, rash, and liver toxicity.

There were two treatment-related deaths in group B due to lung infection and pneumonia. Grade 3-4 leukopenia, neutropenia, vomiting, and neurotoxicity were also reported.

The median overall survival for groups A and B was 18.1 and 18.3 months, respectively.

This study was supported by AstraZeneca, makers of gefitinib.

Correspondence: Dr. Yi-Long Wu; email:

E-mail to a Friend Email Physician More Information